Study Enrollment

Your details will not be published or shared.

Clinical Trial

A Phase 2, 12-week, Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Evaluate Efficacy, Safety, Tolerability and Pharmacokinetics of 3Dose levels of TAK-831 in Adjunctive Treatment of Adult Subjects with Negative Symptoms of Schizophrenia

The purpose of this study is to determine whether TAK-831 improves negative symptoms of schizophrenia, when taken together with an anti-psychotic medication. Negative symptoms include reduced expression of emotions, reduced feelings of pleasure in everyday life, difficulty beginning and sustaining activities, reduced socializing, and reduced speaking.

Eligibility Criteria

  • Male or female patients age 18-60 years old Diagnosis of schizophrenia Must have an adult designated study partner who will help provide information about your symptoms and how they affect your activites.

Contact Information

    Nesley George

    (706) 721-4857